These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 22235997)
1. Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Marr LA; Gilham DE; Campbell JD; Fraser AR Clin Exp Immunol; 2012 Feb; 167(2):216-25. PubMed ID: 22235997 [TBL] [Abstract][Full Text] [Related]
2. Engineered T cells: the promise and challenges of cancer immunotherapy. Fesnak AD; June CH; Levine BL Nat Rev Cancer; 2016 Aug; 16(9):566-81. PubMed ID: 27550819 [TBL] [Abstract][Full Text] [Related]
3. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144 [TBL] [Abstract][Full Text] [Related]
4. New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. Schmitt TM; Stromnes IM; Chapuis AG; Greenberg PD Clin Cancer Res; 2015 Dec; 21(23):5191-7. PubMed ID: 26463711 [TBL] [Abstract][Full Text] [Related]
5. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369 [TBL] [Abstract][Full Text] [Related]
6. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878 [TBL] [Abstract][Full Text] [Related]
7. Challenges and future perspectives of T cell immunotherapy in cancer. de Aquino MT; Malhotra A; Mishra MK; Shanker A Immunol Lett; 2015 Aug; 166(2):117-33. PubMed ID: 26096822 [TBL] [Abstract][Full Text] [Related]
8. CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy. Bridgeman JS; Ladell K; Sheard VE; Miners K; Hawkins RE; Price DA; Gilham DE Clin Exp Immunol; 2014 Feb; 175(2):258-67. PubMed ID: 24116999 [TBL] [Abstract][Full Text] [Related]
9. Versatile strategy for controlling the specificity and activity of engineered T cells. Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368 [TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. Curran KJ; Pegram HJ; Brentjens RJ J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649 [TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cell Therapy in Hematology. Ataca P; Arslan Ö Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367 [TBL] [Abstract][Full Text] [Related]
12. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy. Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612 [TBL] [Abstract][Full Text] [Related]
13. Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy. Udyavar A; Geiger TL Arch Immunol Ther Exp (Warsz); 2010 Oct; 58(5):335-46. PubMed ID: 20680493 [TBL] [Abstract][Full Text] [Related]
14. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953 [TBL] [Abstract][Full Text] [Related]
15. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer. Zhang Q; Li H; Yang J; Li L; Zhang B; Li J; Zheng J Curr Gene Ther; 2013 Feb; 13(1):65-70. PubMed ID: 23256743 [TBL] [Abstract][Full Text] [Related]
16. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells. Davies DM; Maher J Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):165-78. PubMed ID: 20373147 [TBL] [Abstract][Full Text] [Related]
17. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525 [TBL] [Abstract][Full Text] [Related]
18. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Kochenderfer JN; Rosenberg SA Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520 [TBL] [Abstract][Full Text] [Related]
19. [New immunotherapeutic approaches in oncology and hematology]. Kroemer M; Turco C; Galaine J; Deschamps M; Limat S; Borg C Transfus Clin Biol; 2015 Aug; 22(3):132-40. PubMed ID: 26068883 [TBL] [Abstract][Full Text] [Related]
20. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]